An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819

MiXCR: software for comprehensive adaptive immunity profiling

Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730

Cancer/testis antigens, gametogenesis and cancer

Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388

Cancer ecosystems: A dynamic interplay across scales

Quail, D. F., & Joyce, J. A. (2026) · Cell · doi:10.1016/j.cell.2026.03.003 · Cited by 26

mRNA-based therapies: Preclinical and clinical applications

Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 21

Research progress on non-protein-targeted drugs for cancer therapy

Zhang, Y., Lu, L., Song, F., Zou, X., Liu, Y., Zheng, X., Qian, J., Gu, C., Huang, P. C., & Yang, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02635-y · Cited by 22

The Development of Cell-Penetrating Peptides for Efficient and Selective In Vivo Expression of mRNA in Spleen Tissue

Porosk, L., Härk, H. H., Arukuusk, P., Haljasorg, U., Peterson, P., & Kurrikoff, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030952 · Cited by 22

Current Status and Trends in Nucleic Acids for Cancer Therapy: A Focus on Polysaccharide‐Based Nanomedicines

Molinar, C., Tannous, M., Meloni, D., Cavalli, R., & Scomparin, A. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300102 · Cited by 21

When synthetic biology meets medicine

Feng, Y., Su, C., Mao, G., Sun, B., Cai, Y., Dai, J., & Ma, Y. (2024) · Life Medicine · doi:10.1093/lifemedi/lnae010 · Cited by 21

Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization

Becker, W., Olkhanud, P. B., Seishima, N., Moreno, P. A., Goldfarbmuren, K. C., Maeng, H. M., & Berzofsky, J. A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008970 · Cited by 21

Gene therapy for polygenic or complex diseases

Wu, T., Hu, Y., & Tang, L. V. (2024) · Biomarker Research · doi:10.1186/s40364-024-00618-5 · Cited by 24

Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6

Klepsch, V., Siegmund, K., & Baier, G. (2021) · Cancers · doi:10.3390/cancers13112600 · Cited by 21

Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response

Qi, H., Sun, Z., Gao, T., Yao, Y., Yu, W., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01958-4 · Cited by 21

Nanomedicine and Spleen-Targeting Strategies for Precision Immunomodulation: Advances, Challenges, and Future Perspectives

Oh, C., Jung, H. S., Park, J., Awad, J., Jiang, D., Dowling, D. J., & Im, H. (2025) · ACS Nano · doi:10.1021/acsnano.5c04836 · Cited by 21

Progress in cancer vaccines enabled by nanotechnology

Kim, B., Abdelfattah, N. S., Hostetler, A., & Irvine, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02021-z · Cited by 22

Are There Hidden Genes in DNA/RNA Vaccines?

Beaudoin, C. A., Bartas, M., Volná, A., Pečínka, P., & Blundell, T. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801915 · Cited by 21

Cytotoxicity - Understanding Cellular Damage and Response

Sukumaran, A., & Mansour, M. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100956 · Cited by 22

mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic

Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 21

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Shebbo, S., Binothman, N., Darwaish, M., Niaz, H. A., Abdulal, R. H., Borjac, J., Hashem, A. M., & Mahmoud, A. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1350208 · Cited by 20

Immunocyte membrane-derived biomimetic nano-drug delivery system: a pioneering platform for tumour immunotherapy

Zeng, Y.-Y., Gu, Q., Li, D., Li, A.-X., Liu, R., Liang, J., & Liu, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01355-z · Cited by 20

Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers

Apavaloaei, A., Hesnard, L., Hardy, M., Benabdallah, B., Ehx, G., Thériault, C., Laverdure, J., Durette, C., Lanoix, J., Courcelles, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111241 · Cited by 20

In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines

Meng, S., Hara, T., Miura, Y., Arao, Y., Saito, Y., Inoue, K., Hirotsu, T., Vecchione, A. M., Satoh, T., & Ishii, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073119 · Cited by 23

TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study

Emmers, M., Welters, M. J. P., Dietz, M. V., Santegoets, S. J. A. M., Boekesteijn, S., Stolk, A., Loof, N. M., Dumoulin, D. W., Geel, A., Steinbusch, L. C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60281-8 · Cited by 19

Iterative Screening of Vitamin E-Based Functional Lipid Nanoparticles for mRNA Delivery

Cui, K., Zhang, F., Shi, T., Zhao, S., Zhou, Y., Liu, X., Hu, Y. Y., Hu, Z., Kong, L., & Zhang, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01378 · Cited by 20

Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy

Li, X., Kaboli, P. J., Roozitalab, G., Salahi, S., Qian, H., Zhang, X., Chen, K., & İmani, S. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01199-1 · Cited by 19

Integrating CD4 + T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model

Shibata, H., Xu, N., Saito, S., Zhou, L., Ozgenc, I., Webb, J., Fu, C., Zolkind, P., Egloff, A. M., & Uppaluri, R. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1958589 · Cited by 19

Lipid-mRNA nanoparticles landscape for cancer therapy

Li, Y., Fang, H., Zhang, T., Wang, Y., Qi, T., Li, B., & Jiao, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1053197 · Cited by 20

The self-adjuvant heterocyclic lipid nanoparticles encapsulated with vaccine and STAT3 siRNA boost cancer immunotherapy through DLN-targeted and STING pathway

Liu, Z., Wang, Q., Feng, Y., Zhao, L., Dong, N., Zhang, Y. X., Yin, T., He, H., Tang, X., Gou, J., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.146474 · Cited by 19

Building a Better Silver Bullet: Current Status and Perspectives of Non‐Viral Vectors for mRNA Vaccines

Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 20

Curing Stage IV Melanoma: Where Have We Been and Where Are We?

Chan, P. Y., & Corrie, P. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438654 · Cited by 19

Strategies to Overcome Hurdles in Cancer Immunotherapy

Kim, J. H., Lee, B. J., Moon, S., Lee, H., Lee, J., Kim, B., Jung, K., Seo, H., & Chung, Y. (2024) · Biomaterials Research · doi:10.34133/bmr.0080 · Cited by 19

Nanotechnology platforms for antigen and immunostimulant delivery in vaccine formulations

Márquez, P. G., Wolman, F. J., & Glisoni, R. J. (2024) · Nano Trends · doi:10.1016/j.nwnano.2024.100058 · Cited by 22

Cancer vaccines: an update on recent achievements and prospects for cancer therapy

Chekaoui, A., Garofalo, M., Gad, B., Staniszewska, M., Chiaro, J., Pancer, K. W., Gryciuk, A., Cerullo, V., Salmaso, S., Caliceti, P., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01541-7 · Cited by 21

Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice

Belnoue, E., Leystra, A. A., Carboni, S., Cooper, H. S., Macedo, R. T., Harvey, K. N., Colby, K. B., Campbell, K. S., Vanderveer, L., Clapper, M. L., et al. (2021) · Cancers · doi:10.3390/cancers13040845 · Cited by 19

Recent Advances in the Delivery Carriers and Chemical Conjugation Strategies for Nucleic Acid Drugs

Oyama, S., Yamamoto, T., & Yamayoshi, A. (2021) · Cancers · doi:10.3390/cancers13153881 · Cited by 20

DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor

Wang, C., Zainal, N. S., Chai, S. J., Dickie, J., Gan, C. P., Zulaziz, N., Lye, B. K. W., Sutavani, R. V., Ottensmeier, C. H. H., King, E. V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763086 · Cited by 19

Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model

Kang, J.-H., Lee, H.-J., Lee, J., Hong, J. H., Kim, Y. H., Disis, M. L., Gim, J., & Park, K. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004702 · Cited by 19

RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy

Zhang, H., & Xia, X. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1921524 · Cited by 19

Towards designing improved cancer immunotherapy targets with a peptide-MHC-I presentation model, HLApollo

Thrift, W. J., Lounsbury, N., Broadwell, Q., Heidersbach, A. J., Freund, E. C., Abdolazimi, Y., Phung, Q. T., Chen, J., Capietto, A.-H., Tong, A.-J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54887-7 · Cited by 20

Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines

Li, Y., Xu, Y., Su, W., Xu, J., Ye, Z., Wang, Z., Liu, Q., & Chen, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117897 · Cited by 18

Advances in Vaccine-Based Therapies for Pancreatic Cancer

McMillan, M. T., & Soares, K. C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01165-4 · Cited by 19

Applications of mRNA Delivery in Cancer Immunotherapy

Pan, X., Zhang, Y.-W.-Q., Dai, C., Zhang, J., Zhang, M., & Chen, X. X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s500520 · Cited by 19

Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis

Liu, Y., He, W., Li, X., Lu, X., Wu, C., Gao, Y. J., Fan, D., Dong, C., & Zhao, H. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02321-w · Cited by 19

Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy

Franke, A., Hardet, R., Prager, L., Bentler, M., Demeules, M., John-Neek, P., Jäschke, N. M., Ha, T. C., Hacker, U. T., Adriouch, S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.010 · Cited by 18

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma

Ge, W., Song, S., Qi, X., Chen, F., Che, X., Sun, Y., Wang, J., Li, X., Liu, N., Wang, Q., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.027942 · Cited by 18

Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance

Krykbaeva, I., Bridges, K., Damsky, W., Pizzurro, G. A., Alexander, A. F., McGeary, M. K., Park, K., Muthusamy, V., Eyles, J. E., Luheshi, N., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0699 · Cited by 18

In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery

Henser‐Brownhill, T., Martin, L., Samangouei, P., Ladak, A., Apostolidou, M., Nagel, B., & Kwok, A. (2024) · Advanced Science · doi:10.1002/advs.202401935 · Cited by 18

Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma

Chen, X., Habib, S., Alexandru, M., Chauhan, J., Evan, T., Troka, J. M., Rahimi, A., Esapa, B., Tull, T. J., Ng, W. Z., et al. (2024) · Cancers · doi:10.3390/cancers16193260 · Cited by 18

A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity

Xu, S., Wang, X. H., & Fei, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888556 · Cited by 18

Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression

Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18

Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1): A Promising Cancer Testis Antigen

Bai, R., & Yuan, C. (2022) · Aging and Disease · doi:10.14336/ad.2021.1207 · Cited by 17

RNA nanotechnology: A new chapter in targeted therapy

Lv, T., Meng, Y., Liu, Y., Han, Y., Xin, H., Peng, X., & Huang, J. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113533 · Cited by 17

Poly(ethylene Glycol) (PEG)–OligoRNA Hybridization to mRNA Enables Fine‐Tuned Polyplex PEGylation for Spleen‐Targeted mRNA Delivery

SUZUKI, M. T., Mochida, Y., Hori, M., Hayashi, A., Toh, K., Tockary, T. A., Liu, X., Marx, V., Yokoo, H., Miyata, K., et al. (2024) · Small Science · doi:10.1002/smsc.202300258 · Cited by 17

Mucosal tumor vaccination delivering endogenous tumor antigens protects against pulmonary breast cancer metastases

Oltmanns, F., Antão, A. V., Irrgang, P., Viherlehto, V., Jörg, L., Schmidt, A. P., Wagner, J. T., Rückert, M., Flohr, A.-S., Geppert, C. I., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008652 · Cited by 18

Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?

Tadic, S., & Martı́nez, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433185 · Cited by 19

Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy

Yang, M., Zhong, P., & Wei, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052056 · Cited by 17

How Did We Get a COVID-19 Vaccine in Less Than 1 Year?

Wherry, E. J., Jaffee, E. M., Warren, N. J. H., DʼSouza, G., & Ribas, A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0079 · Cited by 18

mRNA Lipoplexes with Cationic and Ionizable α-Amino-lipophosphonates: Membrane Fusion, Transfection, mRNA Translation and Conformation

Akhter, S., Berchel, M., Jaffrès, P., Midoux, P., & Pichon, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030581 · Cited by 20

Chiral Nanomaterials for Cancer Vaccines

Qu, A., Sun, M., Xu, L., Liu, L., Guo, L., Chen, P., Wang, Q., Du, Z., Wu, Z., Xu, C., et al. (2023) · Small Methods · doi:10.1002/smtd.202301332 · Cited by 17

mRNA vaccine development and applications: A special focus on tumors (Review)

Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., et al. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5669 · Cited by 17

Better, Faster, Stronger: Accelerating mRNA ‐Based Immunotherapies With Nanocarriers

Carvalho, H., Fidalgo, T. A. S., Acúrcio, R. C., Matos, A. I., Satchi‐Fainaro, R., & Florindo, H. F. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2017 · Cited by 16

mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics

Yang, B., Liu, J., Yang, L., & Liu, X. (2025) · Cancer Innovation · doi:10.1002/cai2.70041 · Cited by 18

Melanoma antigens recognized by T cells and their use for immunotherapy

Ohta, S., Misawa, A., Kyi‐Tha‐Thu, C., Matsumoto, N., Hirose, Y., & Kawakami, Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14741 · Cited by 17

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine

Sun, Z., Jing, C., Zhan, H., Guo, X., Suo, N., Kong, F., Tao, W., Xiao, C., Hu, D., Wang, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1097472 · Cited by 16

Natural long-chain saturated fatty acids doped LNPs enabling spleen selective mRNA translation and potent cancer immunotherapy

Wang, F., Zhang, M., Tian, M., Lou, J., Pan, L., Gao, X., Zhang, L., Lou, X., Zhu, L., Sheng, Y., et al. (2023) · Nano Research · doi:10.1007/s12274-023-6111-2 · Cited by 16

Development of Personalized Strategies for Precisely Battling Malignant Melanoma

Isaak, A. J., Clements, G. R., Buenaventura, R. G. M., Merlino, G. T., & Yu, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095023 · Cited by 17

Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study

Forchhammer, S., Pop, O. T., Hahn, M., Aebischer, V., Seitz, C. M., Schroeder, C., Liebmann, A., Abele, M., Wild, H., Bień, E., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03846-0 · Cited by 16

Advances in Vaccines for Melanoma

Cui, C., Ott, P. A., & Wu, C. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.009 · Cited by 16

From promise to progress: the dynamic landscape of glioblastoma immunotherapy

Ijaz, M., Ullah, Z., Aslam, B., Khurshid, M., Chen, P., & Guo, B. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104188 · Cited by 16

The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials

Tapescu, I., Madsen, P. J., Lowenstein, P. R., Castro, M. G., Bagley, S. J., Fan, Y., & Brem, S. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454370 · Cited by 16

Telomerase-based vaccines: a promising frontier in cancer immunotherapy

Vahidi, S., & Touchaei, A. Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03624-7 · Cited by 16

Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination

Chu, Y., Li, R., Qian, L., Liu, F., Xu, R., Meng, F., Ke, Y., Shao, J., Yu, L., Liu, Q., et al. (2021) · Cancer Science · doi:10.1111/cas.15145 · Cited by 17

RNA Secondary Structures Regulate Adsorption of Fragments onto Flat Substrates

Poblete, S., Božič, A., Kanduč, M., Podgornik, R., & Guzman, H. V. (2021) · ACS Omega · doi:10.1021/acsomega.1c04774 · Cited by 16

Roadmap to next-generation cancer vaccines

Zheng, Y., & Zhong, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.005 · Cited by 16

Co-transient expression of PSA-Fc and PAP-Fc fusion protein in plant as prostate cancer vaccine candidates and immune responses in mice

Oh, S., Kim, K., Kang, Y. J., Hwang, H., Kim, Y., Hinterdorfer, P., Kim, M. K., Ko, K., Lee, Y. K., Kim, D., et al. (2023) · Plant Cell Reports · doi:10.1007/s00299-023-03028-3 · Cited by 16

Bacterial couriers as cancer vaccines

Redenti, A., Hahn, J., & Danino, T. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00839-1 · Cited by 16

Advances and Strategies in Enhancing mRNA Cancer Vaccines

Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17

Cancer vaccines: Discovery, development, and challenges for clinical translation

Zhang, Z., Yao, S., Wang, Y., Luo, K., Amiji, M. M., & Anderson, K. C. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123615 · Cited by 15

Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system

Meng, C., Zhang, H., Yi, X., Kong, G., Zhang, X., Wang, B., Xu, Y., Qi, H., Wu, Q., Zhang, K. K., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02480-x · Cited by 15

Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes

Zhang, T., Li, J., Tang, C., Wu, Y., Wu, H., Xi-Tong, Z., Luo, Z., Qin, H., Ding, L., Zeng, Y., et al. (2026) · iMeta · doi:10.1002/imt2.70136 · Cited by 17

An RNA vaccine for advanced melanoma

Bordon, Y. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00417-7 · Cited by 15

Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines

Lim, K. P., & Zainal, N. S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.623475 · Cited by 15

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

Bochem, J., Zelba, H., Spreuer, J., Amaral, T. M. S., Wagner, N. B., Gaißler, A., Pop, O. T., Thiel, K., Yurttas, C., Soffel, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003439 · Cited by 15

Computational design of a broad-spectrum multi-epitope vaccine candidate against seven strains of human coronaviruses

Kumar, A., Rathi, E., & Kini, S. G. (2022) · 3 Biotech · doi:10.1007/s13205-022-03286-0 · Cited by 15

Targeted Drug Delivery to the Spleen and Its Implications for the Prevention and Treatment of Cancer

Khalil, I. A., Faheem, A., & El‐Tanani, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050651 · Cited by 15

The mRNA-Based Innovative Strategy: Progress and Challenges

Zhou, H., Wei, D., Chen, Z., Chen, H., Dong, C., Cai, W., Wang, J., Liu, X., Li, Y., Yang, Y., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-025-01906-x · Cited by 17

Navigating the Biomolecular Corona: Biological Interactions and Therapeutic Implications of RNA–Lipid Nanoparticles

Saini, A., Li, S., Wang, Z., Plebanski, M., & Ju, Y. (2026) · ACS Nano · doi:10.1021/acsnano.6c00334 · Cited by 15

Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection

Arriaga-Canon, C., Contreras‐Espinosa, L., Rebollar‐Vega, R., Montiel-Manríquez, R., Cedro‐Tanda, A., García-Gordillo, J. A., Álvarez-Gómez, R. M., Jiménez-Trejo, F. J., Hernández, C. C., & Herrera, L. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911058 · Cited by 14

Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy

Shim, K., Jo, H., & Jeoung, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914679 · Cited by 14

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy

Hu, C., Liu, J., Cheng, F., Bai, Y., Mao, Q., Xu, M., & Liang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1261243 · Cited by 14

Rational design of polymer-based mRNA delivery systems for cancer treatment

Wan, Q., Sun, Y., Sun, X., & Zhou, Z. (2024) · Polymer Chemistry · doi:10.1039/d4py00206g · Cited by 15

Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity

Bouma, R. G., Twilhaar, M. K. N., Brink, H. J., Affandi, A. J., Mesquita, B. S., Olesek, K., van Dommelen, J. M. A., Heukers, R., de Haas, A. M., Kalay, H., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124254 · Cited by 14

Design of nanosystems for melanoma treatment

Farasatkia, A., Maeso, L., Gharibi, H., Dolatshahi‐Pirouz, A., Stojanović, G. M., Antezana, P. E., Jeong, J., Desimone, M. F., Orive, G., & Kharaziha, M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124701 · Cited by 14

The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade

Bao, Y., Cruz, G., Zhang, Y., Qiao, Y., Mannan, R., Hu, J., Yang, F., Gondal, M. N., Shahine, M., Kang, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0435 · Cited by 16

mRNA vaccines as cancer therapies

Huang, S., Que, H., Wang, M., & Wei, X. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003455 · Cited by 14

Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives

Kanp, T., Dhuri, A., Bharath, M., Rode, K., Aalhate, M., Paul, P., Nair, R., & Singh, P. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01797 · Cited by 14

Synthetic RNA Therapeutics in Cancer

Han, Y., Shin, S.-H., Lim, C. G., Heo, Y. H., Choi, I. Y., & Kim, H. H. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001587 · Cited by 14

Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review)

Volovăț, S. R., Negru, S. M., Stolniceanu, C. R., Volovat, C. D., Lungulescu, C. V., Scripcariu, D. V., Cobzeanu, B. M., Ştefănescu, C., Grigorescu, C., Augustin, I. G., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9967 · Cited by 14

mRNA Vaccine Technology Beyond COVID-19

Oloruntimehin, E. S., Akinyi, F. T., Paul, M., & Ariyo, O. E. (2025) · Vaccines · doi:10.3390/vaccines13060601 · Cited by 13

Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control

Peng, K., Zhao, X., Li, H., Fu, Y., & Liang, Y. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241454 · Cited by 14

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma

Dutta, D., Liu, J., Wen, K., Ray, A., Salatino, A., Liu, X., Gullà, A., Hideshima, T., Song, Y. Y., & Anderson, K. C. (2025) · Blood · doi:10.1182/blood.2025028597 · Cited by 14

Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation

Kim, C., Lee, Y., Lee, H., & Kim, B. (2025) · Small Methods · doi:10.1002/smtd.202501401 · Cited by 13

Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection

Agbosu, E., Ledger, S., Kelleher, A. D., Wen, J., & Ahlenstiel, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071352 · Cited by 13

A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma.

Loquai, C., Hassel, J. C., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Gold, M., Schwarck-Kokarakis, D., Attig, S., Ćuk, K., Vogler, I., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3136 · Cited by 22

An RNA vaccine for advanced melanoma

Bordon, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00145-6 · Cited by 5

An RNA Vaccine Promotes Response with or without Anti–PD-1 in Melanoma

(2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2020-115

549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion

Loquai, C., Hassel, J. C., Bruck, P. T., Derhovanessian, E., Ćuk, K., Lörks, V., Sikorski, J., Gold, M., Maurus, D., Schwarck-Kokarakis, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.549 · Cited by 11

772 Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy

Doonan, B. P., Shaw, C., Lee, J., Manso, E. S., Méndez-Gómez, H., Roemeling, C. A. V., Mitchell, D. A., & Sayour, E. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-sitc2023.0772 · Cited by 3